MEDICENNA THERA CORP (MDNAF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2023, filed Jun 27, 2023. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDNAF SEC filings page.
This page shows MEDICENNA THERA CORP (MDNAF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
MEDICENNA THERA CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
MEDICENNA THERA CORP reported a net loss of $7.4M in fiscal year 2023. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2023.
Not reported for fiscal year 2023.
Not reported for fiscal year 2023.
Cash & Balance Sheet
MEDICENNA THERA CORP held $24.8M in cash as of fiscal year 2023; no long-term debt figure is on record for that period.
Not reported for fiscal year 2023.
Not reported for fiscal year 2023.
Margins & Returns
MEDICENNA THERA CORP's ROE was -34.1% in fiscal year 2023, measuring profit generated per dollar of shareholder equity. This is up 74.3 percentage points from the prior year.
Not reported for fiscal year 2023.
Not reported for fiscal year 2023.
Not reported for fiscal year 2023.
Capital Allocation
MEDICENNA THERA CORP invested $6.9M in research and development in fiscal year 2023. This represents a decrease of 41.7% from the prior year.
Not reported for fiscal year 2023.
Not reported for fiscal year 2023.
MDNAF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, SG&A Expenses, Operating Income, EBITDA, EPS (Diluted), Diluted Shares (Avg).
MDNAF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2310-K | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|---|
| Total Assets | $26.9M+43.4% | $18.8M-44.1% | $33.6M+24.9% | $26.9M |
| Current Assets | $26.9M+43.6% | $18.7M-44.1% | $33.5M+25.1% | $26.8M |
| Cash & Equivalents | $24.8M+51.0% | $16.5M-31.9% | $24.2M+50.3% | $16.1M |
| Total Liabilities | $5.1M+145.1% | $2.1M-35.7% | $3.3M+149.8% | $1.3M |
| Current Liabilities | $2.8M+33.8% | $2.1M-35.7% | $3.3M+154.2% | $1.3M |
| Non-Current Liabilities | $2.3Mn/m | $0n/m | $0-100.0% | $23K |
| Total Equity | $21.8M+30.6% | $16.7M-45.0% | $30.3M+18.5% | $25.6M |
| Retained Earnings | -$59.9Mn/m | -$56.8Mn/m | -$38.5Mn/m | -$22.0M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.
MDNAF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
MDNAF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| MEDICENNA THERA CORP MDNAF | FY2023 | N/A | -$7.4M | N/A | $26.2M | — |
| BioStem Technologies, Inc. BSEM | FY2025 | $47.5M | -$6.6M | -13.9% | $31.0M | 68/100 |
Where MEDICENNA THERA CORP Ranks
Frequently Asked Questions
Is MEDICENNA THERA CORP profitable?
No, MEDICENNA THERA CORP (MDNAF) reported a net loss of $7.4M in fiscal year 2023.
What is MEDICENNA THERA CORP's return on equity (ROE)?
MEDICENNA THERA CORP (MDNAF) has a return on equity of -34.1% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.
What are MEDICENNA THERA CORP's total assets?
MEDICENNA THERA CORP (MDNAF) had $26.9M in total assets as of fiscal year 2023, including both current and long-term assets.
How much does MEDICENNA THERA CORP spend on research and development?
MEDICENNA THERA CORP (MDNAF) invested $6.9M in research and development during fiscal year 2023.
What is MEDICENNA THERA CORP's current ratio?
MEDICENNA THERA CORP (MDNAF) had a current ratio of 9.57 as of fiscal year 2023, which is generally considered healthy.
What is MEDICENNA THERA CORP's liabilities-to-equity ratio?
MEDICENNA THERA CORP (MDNAF) had a liabilities-to-equity ratio of 0.24 as of fiscal year 2023, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2023, because the filing data we hold for that year carries no long-term debt figure.
What is MEDICENNA THERA CORP's return on assets (ROA)?
MEDICENNA THERA CORP (MDNAF) had a return on assets of -27.6% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is MEDICENNA THERA CORP's P/E ratio?
MEDICENNA THERA CORP (MDNAF) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2023). The market capitalization is $26.2M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is MEDICENNA THERA CORP's price-to-sales ratio?
MEDICENNA THERA CORP (MDNAF) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $26.2M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.